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A Randomized Controlled Trial of Screening in the Community to Reduce Fractures in Older 
Women: The SCOOP Study 
SUMMARY 
Background 
Despite effective assessment tools and medications targeting osteoporosis and related fractures, 
screening for fracture risk is not currently advocated in the UK. We tested whether a community- 
based screening intervention could reduce fractures in older women. 
Methods 
We conducted a two-arm randomised controlled trial in women aged 70 to 85 years comparing a 
screening programme using the FRAX risk assessment tool versus usual management. The primary 
outcome was the proportion of individuals experiencing one or more osteoporosis-related fractures 
over a five-year period. In the screening arm, treatment was recommended in women identified to 
be at high risk of hip fracture, according to the FRAX 10-year hip fracture probability. This study was 
registered on the ISRCTN registry (ISRCTN 55814835). 
Findings 
12 483 eligible women, identified from primary care, participated in the trial. Of 6 233 randomised 
to screening, treatment was recommended in 898 (14·4%). Osteoporosis medication use was higher 
at the end of year one in the screening group compared to controls (15·3% vs 4·5%, respectively), 
with uptake particularly higher (78.3% at 6 months) in the screening high risk subgroup. Screening 
did not reduce the incidence of all osteoporosis-related fractures (hazard ratio: 0·94, p=0·178, 95% 
C.I. : 0·85 to 1·03), nor the overall incidence of all clinical fractures (hazard ratio: 0.94, p=0.183, 
95% C.I. : 0.86 to 1.03) but there was strong evidence for a reduction in hip fractures, a pre-
specified secondary outcome (hazard ratio : 0·72, p=0·002 95% C.I. : 0·59 to 0·89). There was no 
evidence of differences in mortality, anxiety levels or quality of life. 
Interpretation 
A systematic, community-based screening programme of fracture risk in older women in the UK is 
feasible. Whilst there was no reduction in overall fracture rate the intervention was effective in 
reducing hip fractures by an estimated 28%. 
Funding 
The Arthritis Research United Kingdom (ARUK), formerly the Arthritis Research Campaign (ARC), and 
the Medical Research Council (MRC) of the UK jointly funded this trial. 
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Introduction 
 
There are approximately 9 million osteoporotic or fragility (low trauma) fractures worldwide per 
year.1 In developed nations, around one in three women and one1 in five men aged 50 years or 
more will suffer a fragility fracture during their remaining lifetime, most commonly at sites such as 
the hip, distal forearm, vertebrae and humerus. In the UK, around 536 000 people suffer fragility 
fractures each year, including 79 000 hip fractures, with a cost in 2010 estimated at £3·5 billion 
expected to rise to £5·5 billion per year by 2025.2 For the individual, a hip fracture can be 
devastating with loss of independence and less than one third of patients making a full recovery; 
mortality at one year post-fracture is approximately 20%.3 
 
Advances in osteoporosis management over the last two decades include development of effective 
low-cost treatments and easily accessible fracture risk assessment tools, such as FRAX®. Bone 
mineral density (BMD) measurement alone has a relatively low sensitivity for fracture risk and is 
therefore of limited utility for mass screening;4,5 the FRAX tool, however, has been shown to 
increase the sensitivity for fracture risk above that provided by measuring BMD in isolation.6 
Although underpinning many guidelines internationally, no formal studies have prospectively 
examined the utility of using FRAX to target intervention and reduce fracture incidence. 
 
The aim of the SCOOP (‘screening for prevention of fractures in older women’) trial was to assess the 
effectiveness of a FRAX-based, community screening programme for UK women aged 70 to 85 years 
in reducing the incidence of fractures over a five year period. 
 
Methods 
Study Design 
The SCOOP clinical study was a pragmatic, unblinded, two group, parallel, randomised controlled 
trial to assess the effectiveness and cost-effectiveness of screening to prevent fractures in older 
women. Details of the methods have been published.7 
The primary end-point was the proportion of participants experiencing at least one osteoporosis- 
related fracture, defined in more detail below, over the five-year follow-up. Follow-up data 
collection points were at 6, 12, 24, 36, 48 and 60 months post-randomisation. 
Participants 
Participants in or around seven regions in England: Norwich, Southampton, Bristol, Birmingham, 
Manchester, York and Sheffield. Women age 70-85 years were identified through primary care lists). 
Those currently on prescription anti-osteoporotic medications (excluding vitamin D or calcium) were 
excluded (though anyone who had used such medication at any time in the past could be included); 
any individuals deemed, by their family doctor, to be unsuitable to enter a research study (e.g. 
known dementia, terminally ill, recently bereaved, etc.) were also excluded. 
Where a large number of potential participants were identified, a number were excluded, at 
random, to ensure for practical reasons that no practice had more than 500 participants. 
Written, informed consent was obtained from all participants. At this point, a self-filled 
questionnaire captured the FRAX risk factors prior to each woman being randomised to the 
intervention (screening) or control arm. Baseline data comprised age, sex, height and weight for 
Body Mass Index (BMI) calculation, and dichotomised risk variables including a prior fragility fracture 
since the age of 50 years, parental history of hip fracture, current tobacco smoking, any long-term 
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use of oral glucocorticoids, rheumatoid arthritis, other causes of secondary osteoporosis and 
daily alcohol consumption of ≥3 units daily. If the respondent did not know the answer to an 
individual question a negative response was assumed. 
Randomisation 
Allocation to study arm was conducted using blocked randomisation (block length 6), stratified 
by recruiting region and age group (70 to 74 years, 75 to 79 years and 80 to 85 years). 
Randomisation was carried out, once relevant data were obtained, using an on-line web-based 
system. This was set up by an independent data-programmer from the Norwich Clinical Trials 
Unit. A 1:1 allocation ratio was used. 
Intervention Arm 
In the screening arm, the baseline risk factor questionnaire was used to calculate the 10-year 
probability of hip and major osteoporotic fracture using the FRAX risk algorithm.8 The hip fracture 
probability was then used to decide whether or not a participant should be invited for a DXA scan 
to assess BMD.  The 10-year probability of hip fracture for each participant was compared to an 
assessment threshold for each 5-year age-band (column 1, Table 1), as determined previously in 
an analysis of treatment cost-effectiveness in the UK. 9 Each participant was classified as low or 
high risk of fracture, depending on whether their individual 10-year hip fracture probability was 
below or above the threshold probability for their age. Participants classified as low risk received 
a letter (also notified to their GP) confirming their low risk status with a recommendation that no 
further action was necessary. The remaining participants were invited to undergo a local, DXA-
based femoral neck BMD measurement and the 10-year hip fracture probability was recalculated 
with inclusion of BMD. Height and weight were measured at the DXA visit and the BMI 
information updated. The presence of rheumatoid arthritis was removed from this calculation as 
it may have been confused with osteoarthritis by participants and reliance on self-report of 
rheumatoid arthritis is not recommended for the FRAX algorithm.10 The final risk category, either 
low or high risk of fracture,(i.e. below or above the age category intervention threshold, column 
2, Table 1) was communicated to the participant and GP by letter; participants above the 
threshold were advised to make an appointment with their family doctor to discuss treatment 
options. 
Control Arm 
Apart from a letter to the GP informing them of their patient participating in the study, no 
additional information was provided and they received standard care as usual. The baseline 10-
year fracture probabilities, without the inclusion of BMD, were calculated at the end of the trial 
for comparative purposes only. 
Outcomes 
The primary outcome was the proportion of participants experiencing at least one osteoporosis- 
related fracture during the five-year follow-up period. Pre-specified secondary outcomes were 
the proportions of participants experiencing at least one hip fracture; any clinical fracture; and 
mortality. Mortality was ascertained by flagging all randomized subjects via the Office of National 
Statistics (ONS); deaths notified by family members and GPs were also confirmed by ONS data.  
The impacts on anxiety (using the short 6-item version of the State-Trait Anxiety Index (STAI)11) 
and health related quality of life (measured with EQ-5D and SF-12) were also pre-specified 
secondary endpoints.   Family doctors were asked to record any adverse events related to the 
screening process. 
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Fracture Ascertainment 
Fracture events were captured from a variety of sources. Participants self-reported any fractures 
occurring since the previous follow-up, including date and anatomical site of fracture, and hospital 
attended (if any). Routine hospital episode statistics (HES) data1, comprising information on 
hospital inpatient stays and emergency department attendance, were interrogated to identify 
fractures in any of the study participants from the point of randomisation until the end of follow-
up. Primary care records were similarly screened for fractures based upon formal Read codes. 
Where self-report or emergency department attendance were the sole source of information, or 
where there was missing information regarding exact dates or anatomical site of fracture, 
further verification included requests to primary care practices and searches of radiology records 
at local hospitals. Vertebral fractures documented within 6 months of randomisation were 
excluded due to uncertainty over the actual date of occurrence. 
Only verified fractures, at any anatomical site, within the five-year follow-up period, were 
included as outcomes. The level of trauma associated with the incident fracture was not 
recorded. Incident osteoporosis-related fractures were defined as those excluding the hands, 
feet, nose, skull or cervical vertebrae. Hip fractures were defined as verified fractures with a 
specific description of ‘neck of femur’ or ‘proximal femur’. Those described as ‘sub-
trochanteric’, ‘femoral shaft’, ‘distal femur’ or simply ‘femoral’ were not categorised as hip 
fractures. 
Statistical Analysis 
Cox’s proportional hazards model was used to estimate the hazard ratio between the two study 
arms for fractures (whether osteoporosis-related, clinical or hip fractures), together with a 95% 
confidence interval. Recruiting region, baseline FRAX risk value (without BMD, to allow use for 
control participants) and self-reported falls at baseline were included in the model. These 
variables were included as prognostic factors and agreed prior to data analysis. Death or 
withdrawal from the study were treated as censoring events. A similar approach was used to 
compare rates of mortality, with study withdrawal as a censoring event. The analysis of quality of 
life data and anxiety data used a general linear model with recruiting region, age and baseline 
value of the outcome included along with treatment arm at each time point. A repeated 
measures linear model (with repeated outcome being at the 6 follow-up time points) was also 
carried out. 
All analyses were conducted on an intention-to-treat basis with participants analysed 
according to the group to which they were randomised, irrespective of whether screening was 
completed. 
Sample Size 
The sample size was based upon the ratio of hazard for the two groups for any osteoporosis-
related fracture over the follow-up period taking into account the expected recruitment time 
and expected censored observations due to death. 12 Assumptions included a 2·5% annual 
incidence of fractures and a death rate of approximately 4·2% per annum in UK women aged 70-
85 years.13,14 Assuming a screening sensitivity of at least 65%, a treatment effect of 35% (i.e. a 
35% relative reduction in fractures in individuals on active treatment), and 80% uptake of 
treatment in the high risk group, a relative reduction in risk of fracture of 18% was estimated, 
i.e. a hazard ratio of around 0·82. This indicated a sample size of 5790 women per arm would 
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provide 90% power with 5% significance based upon the stated hazard ratio; a fracture rate of 
2·0% in the control group would reduce the power to 82%. The target sample size was thus set 
at 11580, with 5790 per arm. 
Ethical Approval and Funding 
Full ethical approval was obtained from the North Western - Haydock Research Ethics 
Committee of England in September 2007 (REC 07/H1010/70). The trial was registered on the 
International Standard Randomised Controlled Trial Register in June 2007 (ISRCTN 55814835). 
The Arthritis Research United Kingdom (ARUK), formerly the Arthritis Research Campaign (ARC), 
and the Medical Research Council (MRC) of the UK jointly funded this trial. 
 
Role of the funding bodies 
 
The funders of the study played no role in the study design, data collection, data analysis, data 
interpretation or writing of this report.  The corresponding author had full access to all data used 
in this study and had final responsibility for the decision to submit for publication. 
 
Findings 
Participants 
Participant progress through the trial is illustrated in Figure 1. A total of 52 033 women aged 70 
to 85 years were identified. Following exclusions for concurrent anti-osteoporosis medication 
use (n=6 927, 13·3%), being deemed unsuitable to enter a research study by their family doctor 
(n=3 473, 6·7%) or other exclusion reasons (n=3 033, 5·8%; e.g. ensuring no more than 500 
participants per practice), letters of invitation were sent to 38 600 women. A further 569 were 
subsequently excluded when found to be using anti-osteoporosis medication, not originally 
noted or initiated after the time of initial identification. Of the 38 031 remaining eligible women, 
11 068(29·1%) didn’t respond (despite a reminder letter) and 13 870 (36·5%) declined to take 
part. Thus, 13 029 women consented to participate, and a total of 12 495 (32·9% of those 
eligible) were randomised. The first randomisation was carried out in April 2008 and the last in 
July 2009. The last follow-up was in July 2014. The number of women randomised in each of the 
seven regions ranged from 1632 to 2055. 
Twelve participants were excluded post-randomisation: nine were on anti-osteoporotic 
medication at randomisation, two were mistakenly entered into the trial twice and one withdrew 
from the trial post-randomisation.  Thus, the results pertain to 12 483 appropriately randomised 
participants. 
Baseline Characteristics 
The screening group comprised 6 233 women with 6 250 in the control group. As expected for a 
randomised trial of this size, the two groups were closely comparable at baseline (Table 2). 
Compared to those declining participation, participants reported a better education, higher 
social- economic status, and more frequent histories of previous fracture or parental hip 
fracture. 
Screening Details 
Approximately half of those in the screening arm (3 064, 49·2%) were categorised as initial high 
risk and were invited to have a DXA scan. Of these, 247 (8·1%) did not provide a BMD result (157 
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declined the invitation, 81 unable to have hip BMD measured and nine died before scan) and 
consequently did not have an updated fracture risk calculated. Of those with BMD measured at 
the femoral neck, 898 (14·4% of the screening arm) were deemed to be at high risk after 
recalculation of their FRAX hip fracture probability (Table 2). The mean femoral neck T-score was 
-2·6 for this group. The average time from randomisation to notification of risk category in those 
invited for a DXA scan was 78 days. 
There were no serious adverse events related to screening recorded.   
Use of anti-osteoporosis medication 
By the end of the first year, 953 participants in the screening arm (15·3% of those randomised to 
the screening arm) had had at least one prescription compared with just 264 (4·5%) in the 
control arm. Exposure to treatment was higher in those categorised as high risk in the screening 
arm with 703 (78·3%) having received at least one prescription within 6 months of 
randomisation. Over the remaining years of follow-up, the proportion on treatment remained 
fairly constant in the screening arm, at around 13% to 14%, whereas there was a steady increase 
in treatment exposure in the control arm, with 833 (10·1%) receiving some prescription 
medication in the final 12 months of follow-up. During the course of the study, around 24% of 
the screening arm participants received at least one prescription for anti-osteoporosis 
medication compared with 16% of the control arm. 
 
Efficacy Outcomes 
The follow-up period provided 59 401 person-years of observation. Table 3 shows details of the 
fracture events by group. Overall, 1 975 osteoporosis-related fractures were identified in 1 657 
individuals, 13·3% of those randomised. The most common site of fracture was the distal 
forearm (614 individuals experienced 638 fractures, 338 in the control arm and 300 in the 
screening arm) followed by the hip (382 individuals experienced 392 fractures, 225 in the 
control arm and 167 in the screening arm). The estimated rate of new clinical fractures per 100 
person years were: overall 3·3, wrists 1·1, hips 0·66. 
Over 5 years, the proportion of individuals experiencing an osteoporosis-related fracture (the 
primary outcome) was similar in the screening arm compared to the control arm (12·9% v 
13·6%) with an adjusted hazard ratio (HR) of 0·94 (p=0.178, 95% C.I. : 0·85 to 1·03). A similar 
result was observed for any clinical fracture (15·3% v 16·0%, HR = 0·94, p=0·183, 95% C.I. : 0·86 
to 1·03). In contrast, in a pre-specified secondary analysis, screening led to a relative reduction 
in hip fractures of 28% compared with usual care (2·6% v 3·5%, HR = 0·72, p=0·002, 95% C.I. : 
0·59 to 0·89). 
Over 5 years, mortality rates were similar in the screening and control arms (8·8% v 
8·4% respectively, HR = 1·05, p=0·436, 95% C.I. : 0·93 to 1·19). 
There was no evidence of any impact of screening on anxiety levels (Table 4, p=0·515, 
repeated measures ANOVA). Those in the high risk group had higher levels of anxiety at 
baseline, prior to screening, but throughout the study period the mean difference between 
the high risk group and low risk group, or between the screening and control groups, were 
extremely small. We found no evidence of an impact on quality of life assessed by the EQ-5D 
or SF-12 (Tables 5 and 6). 
 
 
8 
 
Discussion 
The SCOOP study did not demonstrate an effect of screening for fracture risk on the primary 
outcome of any osteoporosis-related fracture. It did lead to a statistically and likely clinically 
significant decrease in hip fractures. As with any clinical trial, conclusions based upon 
secondary outcomes need to be treated with a degree of caution and not over-emphasised.  
To the best of our knowledge, though, this is the first time that a community-screening 
approach, based upon fracture risk, has demonstrated  any subsequent fracture reductions. 
Indeed,  in 2013, the National Screening Committee of the UK noted an absence of evidence 
supporting the introduction of screening for fracture risk in postmenopausal women;15 the 
one trial of screening identified,16 commencing in the 1990s, was deemed not to provide 
sufficiently current evidence.  An alternative recent approach that screened for prevalent 
vertebral fractures in primary care has shown promise but had treatment uptake as the 
primary outcome, rather than any decrease in fractures, and has not undergone a formal 
cost-effectiveness analysis.17  
 
The SCOOP study has demonstrated the feasibility of a community based, screening programme 
in women aged 70 to 85 years to reduce hip fractures. The overall screening process was 
relatively straightforward. Completion of the initial FRAX questionnaire was very good and the 
DXA scan attendance rate was high; few individuals decided not to, or were unable to, attend for 
a scan. There was no observed increase in average anxiety levels post-screening and an 
integrated qualitative study, conducted at the time of the trial, suggested screening was 
acceptable to both participants and primary care physicians.18 
There are a number of limitations that need to be considered. Participants represented around 
only one third of those eligible. There was evidence of a healthy selection bias; for example, the 
mortality rate over 5 years was less than half of that expected (8·6% versus an expected 19·0%, 
based upon the age distribution at entry).14 Those participating also tended be better educated 
and of a higher socio-economic status than those actively declining.  Only 14% of those screened 
were deemed at high risk, lower than the expected 20-40% of post-menopausal women 
(depending on age) according to the UK NOGG guidelines.19  Nonetheless, the rates of fracture 
observed were actually higher than  predicted prior to the study commencement. The 
discrepancy could be due to a genuine increase in fracture rates since 2001, or an under-
estimation based upon the primary care Read coding recorded in 2001, 13 or perhaps a 
combination of the two factors. 
Whilst there was no evidence that screening might reduce overall osteoporosis-related fracture 
incidence, there was strong evidence for a decrease in hip fractures. A number of reasons need 
to be considered for these results. Contamination with increased uptake of treatment in the 
control arm could have lessened the impact of the intervention; however treatment uptake in 
the first 6 months was very low (20% of that seen in the intervention arm) with a roughly linear 
increase thereafter. This suggests no significant early influence of contamination on prescribing 
in the control arm.   Treatment in the control arm may have increased over time with changes in 
standard management of osteoporosis in primary care subsequent to changes in national or 
local guidelines, hence reducing any between group differences.  This could explain the lack of 
effect regarding all OP-related fractures but would not account for the effect on hip fractures. 
The discrepancy is more likely explained by the screening method which used the 10-year risk of 
hip fracture, rather than the risk of any major osteoporotic fracture. Whilst the FRAX algorithm 
can calculate both, and the two risk values are related, they are not perfectly correlated nor 
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interchangeable. Using the hip fracture risk as the screening approach would, of course, be more 
sensitive to predicting, and therefore better at preventing, hip fractures, rather than fractures at 
other sites. This is likely to explain the discrepancy seen. 
The absolute size of decrease in hip fracture rates was 0·9%, requiring 111 individuals to be 
screened in order to avert one hip fracture. The relative risk reduction of 28%, though somewhat 
less than the 40% reduction observed in clinical trials of osteoporosis medication, is substantial 
given the absence of treatment in the greater majority of the screening group and treatment for 
a proportion of the controls. While it is possible that the reduction was due to more than just an 
effect of prescribed medication, for example the process may have influenced behaviour to 
reduce hip fractures in a selected group more open to the influence of risk information, there is 
little evidence that provision of simple health-related information can substantially reduce 
fracture risk ; studies addressing strategies to reduce fall risk, for example, have not been 
associated with significant decreases in fracture risk.20   The effect seen must also be considered 
in light of the efficacy of current treatment.  With more efficacious therapies available in future 
the rate of hip fracture reduction is likely to increase. 
Analyses of the cost of screening are currently underway and will be published in full elsewhere. 
However, preliminary findings indicate that the cost per prevented osteoporotic-related fracture 
being less than £4 500, and the cost per prevented hip fracture less than £8 000. Additionally, 
the cost per QALY gained, estimated under various scenarios, was less than £20 000.  
In conclusion, despite no overall reduction in fractures, this trial has demonstrated that 
community screening, based upon the FRAX probability of hip fracture, leads to a significant 
reduction in hip fractures in older women. Cost-effectiveness analyses are ongoing but the 
SCOOP study provides promise of an effective community-based management strategy in the 
UK, and elsewhere, to reduce hip fractures. 
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Age Group BMD Threshold Treatment Threshold1 
70-74 5.18% 5.24% 
75-79 6.81% 6.87% 
80-84 8.46% 8.52% 
85 8.39% 8.99% 
1: Post-BMD measurement 
Table 1: Risk Thresholds for invitation for BMD Measurement and Treatment. Based upon the 
FRAX 10-year probability of hip fracture. 
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Non-participants 
(N=15097)1 
Control 
(N=6250) 
Screening 
(N=6233) 
Screened High Risk 
(N= 898) 
 
 
 
Has a degree? Yes 1080 ( 9.9%) 1266 (20.3%) 1270 (20.4%) 182 (20.3%) 
Social Class3 I 570  ( 5.8%) 641 (10.3%) 615  ( 9.9%) 86  ( 9.6%) 
 II 2206 (22.4%) 1827 (29.2%) 1871 (30.0%) 266 (29.6%) 
 IIIN 1651 (16.8%) 1094 (17.5%) 1015 (16.3%) 211 (23.5%) 
 IIIM 3196 (32.5%) 1626 (26.0%) 1622 (26.0%) 163 (18.2%) 
 IV 1476 (15.0%) 718 (11.5%) 1471 (12.1%) 112 (12.5%) 
 V 739  ( 7.5%) 244  ( 3.9%) 250  ( 4.0%) 38  ( 4.2%) 
Ethnic group White 10955 (98.4%) 6160 (98.6%) 6157 (98.8%) 893 (99.4%) 
 Black 66 ( 0.6%) 26  ( 0.4%) 26  ( 0.4%) 1  ( 0.1%) 
 Asian 65 ( 0.6%) 18  ( 0.3%) 25  ( 0.4%) 3  ( 0.3%) 
 Other 47 ( 0.4%) 23   ( 0.4%) 15  ( 0.2%) 1  ( 0.1%) 
Fallen in past year? Yes 2186 (19.9%) 1700 (27.2%) 1744 (28.0%) 295 (33.0%) 
Broken bone since 50? Yes 1859 (17.0%) 1463 (23.4%) 1399 (22.4%) 409 (46.0%) 
Parents broken hip? Yes 536   ( 5.3%) 577  ( 9.2%) 585 ( 9.4%) 354 (41.6%) 
Smoker? Yes 826  ( 7.4%) 290  ( 4.6%) 290 ( 4.7%) 86 ( 9.6%) 
Alcohol units ≥3/day? Yes 383  ( 3.4%) 225  ( 3.6%) 219 ( 3.5%) 60 ( 6.7%) 
Glucocorticoid Use? Yes -- 312  ( 5.0%) 316 ( 5.1%) 113 (13.3%) 
Rheumatoid Arthritis? Yes -- 410 ( 6.6%) 426 ( 6.8%) 79 ( 9.3%) 
Secondary Causes of OP? Yes -- 1408 (22.5%) 1483 (23.8%) 267 (29.7%) 
Age (at response) Mean (SD) 76.8 (5.84) 75.5 (4.14) 75.4 (4.16) 77.2 (4.40) 
BMI Mean (SD) 26.1 (4.90) 26.7 (4.75) 26.7 (4.71) 24.4 (4.06) 
FRAX 10 year HIP 
Fracture Probability2 
Mean (SD) -- 8.5% (7.3%) 8.5% (7.4%) 17.9% (10.9%) 
FRAX 10 year Major OP 
Fracture Probability2 
Mean (SD) -- 19.3% (8.8%) 19.3% (8.9%) 30.0% (10.7%) 
 
1: Percentages are of those providing a non-missing answer. 
3: Prior to BMD results. 
3: Based on the National Readership Survey (NRS) grading : I : higher managerial or professional; II : intermediate managerial or professional; IIIN : Non-manual skilled 
workers; IIIM : Manual skilled workers; IV : Semi-skilled workers; V: unskilled or casual workers 
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Table 2 : Baseline Characteristics 
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 Control Screening  Hazard Ratio1 
(N=6250) (N=6233)  (95% C.I.) 
 
OP-Related 
    
No Fracture 5398 5428   
Fracture 852 (13.6%) 805 (12.9%)  0.94 
    (0.85 , 1.03 ) 
    p=0.178 
Hips     
No Fracture 6032 6069   
Fracture 218  ( 3.5%) 164  ( 2.6%)  0.72 
    (0.59 , 0.89 ) 
    p=0.002 
All Clinical     
No Fracture 5248 5282 
Fracture 1002 (16.0%) 951 (15.3%)  0.94 
 (0.86 , 1.03 ) 
p=0.183 
Mortality 
Survive 5725 5683 
Died 525 ( 8.4%) 550 ( 8.8%)  1.05 
 (0.93 , 1.19 ) 
p=0.436 
1: Adjusted for Recruiting Region, Baseline FRAX Probability and Falls. 
Table 3 : Efficacy Outcomes.  All clinical fractures included all osteoporosis (OP)-related fractures as 
well as fractures of the hands, feet, ankle, face and skull. 
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 Low Risk 
(N=5088) 
High Risk 
(N= 898) 
Control 
(N=6250) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
10.1 (3.65) 
 
10.5 (3.73) 
 
10.2 (3.68) 
 
- 
 
- 
6 Months 10.2 (3.78) 10.2 (3.74) 10.2 (3.67) 0.045 0.961 
12 Months 10.2 (3.71) 10.3 (3.91) 10.2 (3.70) -0.085 0.809 
24 Months 10.2 (3.71) 10.4 (3.76) 10.2 (3.76) -0.154 0.562 
36 Months 10.3 (3.73) 10.5 (3.87) 10.3 (3.73) -0.081 0.756 
48 Months 10.4 (3.78) 10.4 (3.68) 10.4 (3.75) -0.093 0.647 
60 Months 10.5 (3.83) 10.6 (3.70) 10.4 (3.81) -0.184 0.226 
   Repeated Group3 0.515 
   Measures Group*Time4 0.942 
   Analysis   
 
1: Control – High Risk, adjusted for Recruiting Region, Age and Baseline STAI. 
2: Test of any group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 4 : State-Trait Anxiety Inventory (Short Form) over five years follow-up, Mean (SD). This scale 
ranges from 6 to 24, with lower scores indicating lower levels of anxiety. 
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 Intervention 
(N=6233) 
Control 
(N=6251) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
0.74 (0.24) 
 
0.74 (0.23) 
 
- 
 
- 
6 Months 0.74 (0.24) 0.74 (0.24) -0.003 0.394 
12 Months 0.74 (0.25) 0.73 (0.25) -0.010 0.020 
24 Months 0.71 (0.27) 0.72 (0.26) -0.003 0.537 
36 Months 0.68 (0.29) 0.69 (0.28) -0.006 0.273 
48 Months 0.67 (0.31) 0.66 (0.30) -0.008 0.154 
60 Months 0.63 (0.33) 0.63 (0.32) -0.003 0.642 
  Repeated Group3 0.154 
  Measures Group*Time4 0.586 
  Analysis   
 
1: Control – Intervention, adjusted for Centre, Age and Baseline EQ-5D 
2: Test of group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 5 : EQ-5D over five years follow-up (Deaths imputed to zero). 
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 Intervention 
(N=6233) 
Control 
(N=6250) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
45.0 (10.5) 
 
45.3 (10.2) 
 
- 
 
- 
6 Months 44.8 (10.8) 44.8 (10.7) -0.26 0.087 
12 Months 44.5 (11.3) 44.6 (11.3) -0.23 0.182 
24 Months 43.0 (12.7) 43.3 (12.4) -0.06 0.753 
36 Months 41.6 (14.1) 41.7 (13.9) -0.22 0.349 
48 Months 40.1 (15.5) 40.1 (15.3) -0.26 0.317 
60 Months 38.3 (16.7) 38.3 (16.6) -0.20 0.481 
  Repeated Group3 0.237 
  Measures Group*Time4 0.881 
  Analysis   
 
1: Control – Intervention, adjusted for Centre, Age and Baseline SF-12. 
2: Test of group difference 
3: Repeated Measures ANOVA test of between group difference 
4: Repeated Measures ANOVA test of group by time interaction 
Table 6(a): SF-12(Physical Health) over five years follow-up (Deaths imputed to zero). 
  
 Intervention 
(N=6233) 
Control 
(N=6250) 
Estimated 
Difference1 
p-value2 
 
Baseline 
 
53.1 ( 8.5) 
 
53.1 ( 8.5) 
 
- 
 
- 
6 Months 52.4 ( 9.5) 52.2 ( 9.5) -0.24 0.164 
12 Months 51.8 (10.3) 51.6 (10.3) -0.17 0.382 
24 Months 50.8 (12.3) 51.1 (11.9) 0.29 0.210 
36 Months 49.4 (14.3) 49.6 (14.3) 0.07 0.805 
48 Months 47.9 (16.4) 47.9 (16.3) 0.19 0.535 
60 Months 46.0 (18.3) 46.3 (18.2) 0.56 0.103 
  Repeated Group3 0.554 
  Measures Group*Time4 0.056 
  Analysis   
 
1: Control – Intervention, adjusted for Centre, Age and Baseline SF-12. 
2: Test of group difference 
3: Repeated Measures ANOVA test of between group difference 4: 
Repeated Measures ANOVA test of group by time interaction 
Table 6(b): SF-12(Mental Health) over five years follow-up (Deaths imputed to zero). 
